PTC Therapeutics financials
$64.96−1.50%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $806.8M | $937.8M | $698.8M | $538.6M | $380.8M | $307.0M | $264.7M | $194.4M | $82.7M |
| Gross profit | $1.68B | $749.4M | $872.3M | $654.1M | $506.3M | $361.8M | $294.8M | $252.1M | $189.8M | $82.7M |
| Gross margin | 97.3% | 92.9% | 93.0% | 93.6% | 94.0% | 95.0% | 96.0% | 95.2% | 97.6% | 100.0% |
| Operating income | $866.9M | -$302.6M | -$439.5M | -$473.3M | -$374.9M | -$408.5M | -$192.8M | -$96.3M | -$64.3M | -$132.1M |
| Net income | $682.6M | -$363.3M | -$626.6M | -$559.0M | -$523.9M | -$438.2M | -$251.6M | -$128.1M | -$79.0M | -$142.1M |
| Net margin | 39.4% | −45.0% | −66.8% | −80.0% | −97.3% | −115.1% | −82.0% | −48.4% | −40.6% | −171.8% |
| Diluted EPS | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | $-4.17 |
| EBITDA | $896.1M | -$66.6M | $14.9M | -$311.1M | -$303.4M | -$354.4M | -$160.6M | -$70.3M | -$46.6M | -$128.8M |
| Operating cash flow | $711.2M | -$107.7M | -$158.4M | -$356.7M | -$251.3M | -$194.1M | -$98.6M | -$27.6M | -$10.1M | -$103.6M |
| Free cash flow | $702.3M | -$114.2M | -$186.9M | -$388.7M | -$279.5M | -$211.9M | -$112.4M | -$34.7M | -$13.2M | -$105.3M |
| Diluted shares | 88.3M | 76.8M | 74.8M | 71.7M | 70.5M | 66.0M | 58.9M | 46.6M | 39.2M | 34.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $984.6M | $779.7M | $594.0M | $279.8M | $189.7M | $208.8M |
| Short-term investments | $960.7M | $360.0M | $282.7M | $130.9M | $583.7M | $894.8M |
| Total debt | $292.6M | $304.0M | $304.4M | $593.4M | $454.5M | $333.5M |
| Total assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B |
| Total liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B |
| Shareholders' equity | -$205.3M | -$1.10B | -$818.6M | -$347.1M | $1.4M | $482.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology